$1.$ What is Machine Learning?

$2.$ How to include Artificial Intelligence in medical school what kind of public health policy would be required for that?

$3.$ Are there any studies about how Artificial Intelligence is used in diabetes management? What are studies using AI showing? are the outcomes promising?

$4.$ How does Artificial Intelligence in diabetes management work? from a population model to actual diagnosis and treatment?

$5.$ Is there data on how much AI has helped those who were not aware of their diagnoses become aware?

$6.$ Give a specific example of AI in diabetes management and how it is used in this area?

$7.$ Regarding the practical application of AI in diabetes management do different approaches for different groups give different attributes? How so$?$ How do you reconcile? So$,$ what is AI good for?

$8.$ Can or can't AI replace clinical acumen?

$9.$ Do health care providers need to improve clinical documentation skills for AI to work? Is this a stakeholder?

$10.$ Can the following factors be regarded as stakeholders for a framework comprising four building blocks to guide the implementation of sustainable AI healthcare in technologies: $(1)$ training and retention of local expertise, $(2)$ robust monitoring systems, $(3)$ a systems$-$based approach to implementation, and $(4)$ a responsible and inclusive local leadership that includes all stakeholders.

$11.$ If these are the stakeholders, then what are the factors affecting each group?

$12.$ To ensure that AI technology meets industry standards, local AI experts must be formed and retained $$ Which stakeholders are these?

$13.$ To avoid deploying disparate AI$-$driven solutions which international organizations $($such as WHO$)$ can help establish appropriate governance strategies and identify essential areas for investment and interventions?

$14.$ Can the IBM Watson be used for the purpose of AI in diabetes management?

$15.$ Who are the stakeholders and what factors are influencing their decision to design and use AI in diabetes management? Such as $-$ Policy principles and stakeholders for AI in Diabetes.

$16.$ For research into AI in diabetes management who are these groups? $-$ CONSORT$$AI$,$ SPIRIT$$AI$,$ STARD$$AI$.$

$17.$ For Quality assurance and oversight, who is the stakeholder responsible for oversight? FDA? Or someone else?

$18.$ In terms of access, affordability and maintaining the AI system, who pays for AI$?$ Centers for Medicaid and Medicare? Or Insurance companies?

$19.$ Who oversees the Ethics?

$20.$ For collaboration and interoperability, who are the policy makers?

$21.$ When AI creates modernized privacy and security frameworks, who is this affecting? Patients? Hospitals or health care providers?

$22.$ Who is responsible for creating and implementing a National Health AI strategy in Diabetes Management in America?

$23.$ In $2019,$ the World Health Organization released the evidence$$based guidelines for digital health, who is the chief stakeholder for this policy?

$24.$ The FDA issued the $$Artificial Intelligence$/$Machine Learning $($AI$/$ML$)$ Based Software as a Medical Device $($SaMD$)$ Action Plan$$ from the Center for Devices and Radiological Health$$s Digital Health Center of Excellence. Is this different from WHO's policy? Is this guiding health care providers? Or industry patients in the US$?$ Is policy implemented? how?

$25.$ To manage AI implementation, health systems must develop or adjust their general IT governance frameworks $-$ who is the stakeholder for this governance the FDA?

$26.$ Can the FDA use the following $2$ options in the US with respective to diabetes management?

$$ Fully automatic mode: This is used at sites where there is absence of a reliable grader for the blood glucose level. The referral is based on results of AI$.$ Anyone with referrable Diabetes and ungradable retinal images are referred to an internist or ophthalmologist. All referable images and at least $10\%$ of non$-$referable should be preferably graded by an ophthalmologist at a later time.

$$ Assistive $($augmented intelligence$)$ mode: This can be used at sites where there is presence of a reliable grader. The results of AI algorithm are shown to the clinician, and they either accept the AI grade or modify the grade based on their clinical judgment.

$27.$ To make diabetes more controllable for patients, do we have any data to reduce the risks associated with diabetes management, such as complications?

$28.$ To invest in AI research and development, who are the stakeholders necessary and how can they be supported? What are the specific tasks that each stakeholder plays in your policy recommendation?

$29.$ To develop incentives for healthcare providers to adopt AI$-$enabled technologies, who are the stakeholders necessary and how can they be supported? What are the specific tasks that each stakeholder plays in your policy recommendation?